A novel biosafety level 2 compliant tuberculosis infection model using a ΔleuDΔpanCD double auxotroph of Mycobacterium tuberculosis H37Rv and Galleria mellonella-Reference-Cited by-同舟云学术

A novel biosafety level 2 compliant tuberculosis infection model using a ΔleuDΔpanCD double auxotroph of Mycobacterium tuberculosis H37Rv and Galleria mellonella

Published:2020-06-24 Issue:1 Volume:11 Page:811-824
ISSN:2150-5594
Container-title:Virulence
language:en
Short-container-title:Virulence

Author:

Asai Masanori¹,Li Yanwen¹,Spiropoulos John²^ORCID,Cooley William²,Everest David²,Robertson Brian D.³^ORCID,Langford Paul R.¹,Newton Sandra M.¹^ORCID

Affiliation:

1. Section of Paediatric Infectious Disease, Department of Infectious Disease, Imperial College London, London, UK

2. Department of Pathology, Animal and Plant Health Agency, Addlestone, UK

3. MRC Centre for Molecular Bacteriology and Infection, Department of Infectious Disease, Imperial College London, London, UK

Funder

Biotechnology and Biological Sciences Research Council

National Centre for the Replacement, Refinement and Reduction of Animals in Research

Publisher

Informa UK Limited

Subject

Infectious Diseases,Microbiology (medical),Immunology,Microbiology,Parasitology

Link

https://www.tandfonline.com/doi/pdf/10.1080/21505594.2020.1781486

Reference39 articles.

1. Building a tuberculosis-free world: The Lancet Commission on tuberculosis

2. TB Alliance. Pretomanid and BPaL [Internet]. 2019. https://www.tballiance.org/access/pretomanid-and-bpal-regimen[Accessed 10 December 2019]

3. Bedaquiline and delamanid in tuberculosis

4. What Have We Learnt about BCG Vaccination in the Last 20 Years?

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Repurposing an Antioxidant to Kill Mycobacterium tuberculosis by Targeting the 50S Subunit of the Ribosome;Biomolecules;2023-12-14

2. Galleria mellonella–intracellular bacteria pathogen infection models: the ins and outs;FEMS Microbiology Reviews;2023-03

3. Tuberculosis: Experimental Models, Innovations, and Challenges;Recent Advances in Pharmaceutical Innovation and Research;2023

4. Progress in the Development of New Vaccines Against Tuberculosis;Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges;2023

5. Galleria mellonella as an infection model for the virulent Mycobacterium tuberculosis H37Rv;Virulence;2022-09-11